1.Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy in NSCLC.
Wei RAO ; Yutao LIU ; Yan LI ; Lei GUO ; Tian QIU ; Lin DONG ; Jianming YING ; Weihua LI
Frontiers of Medicine 2023;17(3):493-502
Anaplastic lymphoma kinase (ALK) is the most common fusion gene involved in non-small cell lung cancer (NSCLC), and remarkable response has been achieved with the use of ALK tyrosine kinase inhibitors (ALK-TKIs). However, the clinical efficacy is highly variable. Pre-existing intratumoral heterogeneity (ITH) has been proven to contribute to the poor treatment response and the resistance to targeted therapies. In this work, we investigated whether the variant allele frequencies (VAFs) of ALK fusions can help assess ITH and predict targeted therapy efficacy. Through the application of next-generation sequencing (NGS), 7.2% (326/4548) of patients were detected to be ALK positive. On the basis of the adjusted VAF (adjVAF, VAF normalization for tumor purity) of four different threshold values (adjVAF < 50%, 40%, 30%, or 20%), the association of ALK subclonality with crizotinib efficacy was assessed. Nonetheless, no statistical association was observed between median progression-free survival (PFS) and ALK subclonality assessed by adjVAF, and a poor correlation of adjVAF with PFS was found among the 85 patients who received first-line crizotinib. Results suggest that the ALK VAF determined by hybrid capture-based NGS is probably unreliable for ITH assessment and targeted therapy efficacy prediction in NSCLC.
Humans
;
Carcinoma, Non-Small-Cell Lung/pathology*
;
Anaplastic Lymphoma Kinase/therapeutic use*
;
Crizotinib/therapeutic use*
;
Lung Neoplasms/pathology*
;
Protein Kinase Inhibitors/pharmacology*
;
Gene Frequency
2.A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.
Wenjia SUN ; Jing ZHENG ; Jianya ZHOU ; Jianying ZHOU
Journal of Zhejiang University. Medical sciences 2023;52(5):583-587
A 54-year-old, non-smoking woman was diagnosed as stage ⅣB adenocarcinoma with widespread bone metastasis (cT4N2M1c) in the First Affiliated Hospital, Zhejiang University School of Medicine. Immunohistochemistry result showed the presence of anaplastic lymphoma kinase (ALK) gene rearrangement; next-generation sequencing (NGS) indicated EML4-ALK fusion (E6:A20) with concurrent CCDC148-ALK (C1:A20), PKDCC-ALK (Pintergenic:A20)and VIT-ALK (V15:A20) fusions. After 32 weeks of alectinib treatment, the patient complained cough and exertional chest distress but had no sign of infection. Computed tomography (CT) showed bilateral diffuse ground glass opacities, suggesting a diagnosis of alectinib-related interstitial lung disease (ILD). Following corticosteroid treatment and discontinuation of alectinib, clinical presentations and CT scan gradually improved, but the primary lung lesions enlarged during the regular follow-up. The administration of crizotinib was then initiated and the disease was stable for 25 months without recurrence of primary lung lesions and ILD.
Female
;
Humans
;
Middle Aged
;
Carcinoma, Non-Small-Cell Lung/drug therapy*
;
Crizotinib/therapeutic use*
;
Lung Neoplasms/drug therapy*
;
Anaplastic Lymphoma Kinase/therapeutic use*
;
Lung Diseases, Interstitial/diagnosis*
3.Treatment of ALK Positive Non-small Cell Lung Cancer with Alectinib: A Case Report and Literature Review.
Chinese Journal of Lung Cancer 2021;24(9):673-676
Lung cancer is a malignant tumor with high incidence rate and mortality rate in China and even the whole world, of which non-small cell lung cancer accounts for about 80%. Anaplastic lymphoma kinase (ALK) gene mutation accounts for about 5%. Alectinib, ALK-tyrosine kinase inhibitor (ALK-TKI), has great performance in clinical. The early detection and treatment of adverse drug reactions can greatly improve clinical benefits. This paper reports a patient of ALK positive non-small cell lung cancer was admited to Baotou Central Hospital in April 2020. The diagnosis and treatment was retrospectively analyzed, and the literature was reviewed.
.
Anaplastic Lymphoma Kinase/genetics*
;
Antineoplastic Agents/therapeutic use*
;
Carbazoles/therapeutic use*
;
Carcinoma, Non-Small-Cell Lung/secondary*
;
Humans
;
Lung Neoplasms/pathology*
;
Mutation
;
Piperidines/therapeutic use*
;
Pleural Neoplasms/secondary*
;
Protein Kinase Inhibitors/therapeutic use*
;
Retrospective Studies
;
Tomography, X-Ray Computed
4.Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer.
Peng SONG ; Li ZHANG ; Congcong SHANG
Chinese Journal of Lung Cancer 2018;21(9):703-711
The incidence of ALK gene rearrangement in non-small cell lung cancer (NSCLC) was about 3% to 5%. ALK gene inhibitors have made great breakthrough in recent years, significantly extending the survival period of patients with ALK(+) advanced NSCLC. But the majority of patients will be acquired drug resistance after treatment. This article has been explained separately from the ALK genetic background, the detection method, the treatment of the three generations of ALK inhibitors and the strategy after drug resistance. It is desire to have reference value and reference meaning for clinical work.
.
Anaplastic Lymphoma Kinase
;
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
enzymology
;
genetics
;
Drug Resistance, Neoplasm
;
genetics
;
Gene Fusion
;
Humans
;
Lung Neoplasms
;
drug therapy
;
enzymology
;
genetics
;
Protein Kinase Inhibitors
;
pharmacology
;
therapeutic use
;
Receptor Protein-Tyrosine Kinases
;
antagonists & inhibitors
;
genetics
5.Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation Treated with Ensartinib: A Case Report and Literature Review.
Donglai LV ; Chunwei XU ; Chong WANG ; Qiuju SANG
Chinese Journal of Lung Cancer 2023;26(1):78-82
Lung squamous cell carcinoma (LSCC) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases and is the second most common histological type of lung cancer. Anaplastic lymphoma kinase (ALK)-positive NSCLC accounts for only 2%-5% of all NSCLC cases, and is almost exclusively detected in patients with lung adenocarcinoma. Thus, ALK testing is not routinely performed in the LSCC population, and the efficacy of such treatment for ALK-rearranged LSCC remains unknown. Echinoderm microtubule associated protein like 4 (EML4)-ALK (V1) and TP53 co-mutations were identified by next generation sequencing (NGS) in this patient with advanced LSCC. On December 3, 2020, Ensatinib was taken orally and the efficacy was evaluated as partial response (PR). The progression-free survival (PFS) was 19 months. When the disease progressed, the medication was changed to Loratinib. To our knowledge, Enshatinib created the longest PFS of ALK-mutant LSCC patients treated with targeted therapy since literature review. Herein, we described one case treated by Enshatinib involving a patient with both EML4-ALK and TP53 positive LSCC, and the relevant literatures were reviewed for discussing the treatment of this rare disease.
.
Humans
;
Carcinoma, Non-Small-Cell Lung/drug therapy*
;
Lung Neoplasms/pathology*
;
Anaplastic Lymphoma Kinase/metabolism*
;
Carcinoma, Squamous Cell/genetics*
;
Mutation
;
Cytoskeletal Proteins/genetics*
;
Lung/pathology*
;
Oncogene Proteins, Fusion/genetics*
;
Protein Kinase Inhibitors/therapeutic use*
;
Tumor Suppressor Protein p53/genetics*
6.Advanced Pneumonic-type Lung Carcinoma: A Retrospective Study of Clinical-radiological-pathological Characteristics with Survival Analysis in A Single Chinese Hospital.
Yongjian LIU ; Ji LI ; Shibo WANG ; Minjiang CHEN ; Jing ZHAO ; Delina JIANG ; Wei ZHONG ; Yan XU ; Mengzhao WANG
Chinese Journal of Lung Cancer 2019;22(6):329-335
BACKGROUND:
Pneumonic-type lung carcinoma is a special type of lung cancer both clinically and radiologically. Here we present our experience on pneumonic-type lung carcinoma in an attempt to investigate the clinical, radiological and pathological features, diagnostic procedures, treatment, and prognosis of this type of tumor.
METHODS:
Pathologically confirmed lung cancer with a chest CT characterized by ground glass opacity or consolidation was defined as pneumonic-type lung carcinoma. Cases with advanced pneumonic-type lung carcinoma admitted to Peking Union Medical College Hospital (PUMCH) from January 1, 2013 to August 30, 2018 were enrolled. Retrospective analysis of clinical data and survival follow-up of these patients was conducted.
RESULTS:
A total of 46 cases were enrolled, all of which were adenocarcinoma. Cough (41/46, 89.1%) and expectoration (35/46, 76.1%) were the most prominent symptoms. The most frequent chest CT findings were ground glass attenuation (87.0%), patchy consolidation (84.8%), and multiple ground-glass nodules (84.8%). Multiple cystic changes (40%) and cavitation (13%) were also quite frequent. Ipsilateral and contralateral intrapulmonary metastasis were noted in 95.3% and 84.8% of cases respectively. The median duration from symptom onset to diagnosis was 214 days (95%CI: 129-298). Both surgical lung biopsy and CT-guided percutaneous lung biopsy had a diagnostic yield of 100%. Transbronchial lung biopsy (TBLB) combined with bronchoalveolar lavage (BAL) had a diagnostic yield of 80.9% (17/21). Sputum cytology had a diagnostic yield of 45% (9/20). Twenty-six cases were invasive mucinous adenocarcinoma (26/46, 56.5%) and the remainder were unable to identify pathological subtypes due to lack of adequate biopsy sample size. EGFR mutation was detected in 15.8% (6/38) of patients and ALK rearrangement was detected in 3.0% (1/33) of patients. The median overall survival for these patients was 522 d (95%CI: 424-619). In patients without EGFR mutation or ALK rearrangement, chemotherapy significantly improved survival (HR=0.155, P=0.002,2). The median overall survival was 547 d (95%CI: 492-602 d) with chemotherapy and 331 d (95%CI: 22-919) without chemotherapy.
CONCLUSIONS
Diagnosis of pneumonic-type carcinoma is usually delayed due to clinical and radiological features mimicking pulmonary infection. TBLB combined with BAL has a quite high diagnostic yield. The most frequent histological type is invasive mucinous adenocarcinoma. The incidence of EGFR mutation or ALK rearrangement is low in pneumonic-type carcinoma. For patients without cancer driver genes, chemotherapy is recommended to improve overall survival.
Aged
;
Anaplastic Lymphoma Kinase
;
genetics
;
metabolism
;
Antineoplastic Agents
;
therapeutic use
;
Carcinoma
;
diagnostic imaging
;
drug therapy
;
genetics
;
pathology
;
ErbB Receptors
;
genetics
;
metabolism
;
Female
;
Gene Rearrangement
;
Humans
;
Lung Neoplasms
;
diagnostic imaging
;
drug therapy
;
genetics
;
pathology
;
Male
;
Middle Aged
;
Mutation
;
Neoplasm Staging
;
Retrospective Studies
;
Survival Analysis
;
Tomography, X-Ray Computed